You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

BROMOCRIPTINE MESYLATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for bromocriptine mesylate and what is the scope of freedom to operate?

Bromocriptine mesylate is the generic ingredient in three branded drugs marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Ss Pharma, Aurobindo Pharma Usa, Padagis Us, Sandoz, and Veroscience, and is included in eight NDAs. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bromocriptine mesylate has thirty-two patent family members in thirteen countries.

There are eight drug master file entries for bromocriptine mesylate. Nine suppliers are listed for this compound.

Summary for BROMOCRIPTINE MESYLATE
Drug Prices for BROMOCRIPTINE MESYLATE

See drug prices for BROMOCRIPTINE MESYLATE

Recent Clinical Trials for BROMOCRIPTINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andrew Moshfeghi, MD, MBAPhase 1/Phase 2
Case Western Reserve UniversityPhase 1/Phase 2
VeroSciencePhase 1

See all BROMOCRIPTINE MESYLATE clinical trials

Pharmacology for BROMOCRIPTINE MESYLATE
Drug ClassErgot Derivative
Medical Subject Heading (MeSH) Categories for BROMOCRIPTINE MESYLATE

US Patents and Regulatory Information for BROMOCRIPTINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan BROMOCRIPTINE MESYLATE bromocriptine mesylate CAPSULE;ORAL 077226-001 Apr 4, 2005 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 074631-001 Jan 13, 1998 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Usa BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 076962-001 Sep 24, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BROMOCRIPTINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ⤷  Sign Up ⤷  Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ⤷  Sign Up ⤷  Sign Up
Ss Pharma PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ⤷  Sign Up ⤷  Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ⤷  Sign Up ⤷  Sign Up
Ss Pharma PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BROMOCRIPTINE MESYLATE

Country Patent Number Title Estimated Expiration
Australia 2013256558 Bromocriptine formulations ⤷  Sign Up
Brazil PI1009619 método para tratar um distúrbio metabólico ou elementos chaves de um distúrbio metabólico e forma de dosagem farmacêutica ⤷  Sign Up
European Patent Office 4342536 FORMULATIONS DE BROMOCRIPTINE (BROMOCRIPTINE FORMULATIONS) ⤷  Sign Up
Japan 2012529434 ⤷  Sign Up
Spain 2755081 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.